Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies—Development and Validation of the ABPS Score

Abstract

Rationale and objectivesTransarterial chemoembolization (TACE) plus molecular targeted therapies has emerged as the main approach for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). A robust model for outcome prediction and risk stratification of recommended TACE plus molecular targeted therapies candidates is lacking. We aimed to develop an easy-to-use tool specifically for these patients. MethodsA retrospective analysis was conducted on 384 patients with HCC and PVTT who underwent TACE plus molecular targeted therapies at 16 different institutions. We developed and validated a new prognostic score which called ABPS score.Additionally, an external validation was performed on data from 200 patients enrolled in a prospective cohort study. ResultsThe ABPS score (ranging from 0 to 3 scores), which involves only Albumin-bilirubin (ALBI, grade 1：0 score；grade 2：1 score), PVTT(I-II type：0 score；III-IV type：1 score), and systemic-immune inflammation index (SII,<550×1012：0 score；≥550×1012：1 score). Patients were categorized into three risk groups based on their ABPS score: ABPS-A, B, and C (scored 0, 1-2, and 3, respectively). The concordance index (C-index) of the ABPS scoring system was calculated to be 0.802, significantly outperforming the HAP score (0.758), 6-12 (0.712), Up to 7 (0.683), and ALBI (0.595) scoring systems (all P< 0.05). These research findings were further validated in the external validation cohorts. ConclusionsThe ABPS score demonstrated a strong association with survival outcomes and radiological response in patients undergoing TACE plus molecular targeted therapy for HCC with PVTT. The ABPS scoring system could serve as a valuable tool to guide treatment selection for these patients.